(ETNB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C.

Weiss Ratings reiterated their sell (d-) rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research note released on Saturday,Weiss Ratings reports. A number of other research analysts also ...

These purchases signal continued confidence in 89bio's prospects, as the company continues its work in pharmaceutical ...

In this article, we are going to take a look at where 89bio, Inc. (NASDAQ:ETNB) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of ...

Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

H.C. Wainwright reiterated its Buy rating and $29.00 price target for 89bio Inc . (NASDAQ:ETNB) shares. According to InvestingPro data, the stock currently trades at $6.31, near its 52-week low of $5.

At close: December 23 at 12:40:29 PM EST ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.

House G.O.P. Floats Medicaid Cuts and More to Finance Trump’s Huge Agenda President Trump wants a massive tax cut and immigration crackdown bill. Republicans must decide what to cut to help pay ...